Jorge Cortell

Senior Advisor, Health Care and Life Sciences

2023 - Current

Responsible for the Health and Life Sciences program and cohort in an ecosystem that exists to support Harvard students and select alumni in their quest to explore game-changing innovation and entrepreneurship. Since our founding in 2011, we’ve helped thousands of founders — from all 13 Harvard schools — to create global, lasting change.

Expert in Residence

2022 - 2023

The Harvard i-lab works with hundreds of student startups each year. We advance seed-stage alumni ventures through our LLX GEO program, and we support high-potential life sciences venture teams through the i-lab student program and Pagliuca Harvard Life Lab. https://innovationlabs.harvard.edu/expert-resources/

Executive Director - Technology and Entrepreneurship Center at Harvard Tokyo Hub

2025

Bringing Harvard University faculty, researchers, and entrepreneurs, and Japanese corporations, entrepreneurs, investors, and universities, closer together to explore academic, partnering, and commercial opportunities through a multi-year program of presentations, lectures, workshops, networking, guest speakers, competitions and more.

Visiting Professor

2025

Lecturing on Global Business Development at the Center for Medical Innovation, Institute of Science Tokyo (University).

Senior International Innovation Fellow

2023

Setting up international projects at the Technology and Entrepreneurship Center at Harvard (TECH).

Venture Innovation Fellow

2022 - 2023

Working on healthtech venture development and life science innovation through a full-time appointment as a Fellow of the Harvard University John A. Paulson School of Engineering and Applied Sciences (SEAS) Technology and Entrepreneurship Center (TECH), where I chair executive education programs such as Industry Leaders Network: Innovation in Healthcare.

Advisory Board Member

2023

Lysando is the world leader in the development of antimicrobial proteins, so‐called Artilysin® molecules. They can effectively eliminate problem‐causing bacteria without associated high risk of resistance formation and microbial disbalances.

Advisory Board Member

2024

AugMend is a data-driven digital therapeutics platform leveraging virtual reality, bio-feedback and Al to unburden clinicians, reduce their waitlists and increase standard of care.

Advisor

2023 - 2023

Venture Partner

2021 - 2023

At NLC, we have built +100 ventures since 2015, +80 still actively managed, securing over 85 million EUR from 273 financing events. I've cofounded/built several in my portfolio like: Flash Pathology (exited), Pryfiber, Matermend, Omicsystems, BiomedBrite, Genotell, 3DSF... while also managing University accounts like NYU, Columbia, Harvard, CSIC... Just in 2022 we analyzed 2500 inventions, building 22 ventures originating in 9 countries, investing over 4 million EUR, and hired 31 CEOs (16% female, 31% from outside Europe).

Founder, CEO & Chief Innovation Officer

2005 - 2021

Enterprise clinical data management and workflow computational bioinformatics platform (AI, medical imaging, digital pathology, clinical genomics, pharmacogenomics and biosensors). Invented 1st Precision Medicine Software Platform (2014), 1st vendor-neutral Digital Pathology Dicomizer (2012), pioneer developer of Augmented Reality in Surgery (2009); employees in 5 countries; >750M medical images & >4M clinical reports managed; self-funded through profits, $MM sales in 12 countries to customers like NHS (UK), American College of Radiology (USA), Bumrungrad (Thailand); #1 brand in Mexico and Peru; IBM, Google, and Microsoft partners.

Member of the Expert Group on Venture Philanthropy and Social Investments

2016 - 2018

Co-authored the official report: Driving Progress for Research and Innovation in Europe

Co-founder, Board Member and Advisor

2014 - 2016

As advisor for the USA market, I identified interesting European IP in Life Sciences and HealthTech, and introduced it to USA investors. Sold in less than 3 years.